The end of the microarray Tower of Babel: will universal standards lead the way?
Microarrays are the most common method of studying global gene expression, and may soon enter the realm of FDA-approved clinical/diagnostic testing of cancer and other diseases. However, the acceptance of array data has been made difficult by the proliferation of widely different array platforms with gene probes ranging in size from 25 bases (oligonucleotides) to several kilobases (complementary DNAs or cDNAs). The algorithms applied for image and data analysis are also as varied as the microarray platforms, perhaps more so. In addition, there is a total lack of universally accepted standards for use among the different platforms and even within the same array types. Due to this lack of coherency in array technologies, confusion in interpretation of data within and across platforms has often been the norm, and studies of the same biological phenomena have, in many cases, led to contradictory results. In this commentary/review, some of the causes of this confusion will be summarized, and progress in overcoming these obstacles will be described, with the goal of providing an optimistic view of the future for the use of array technologies in global expression profiling and other applications.
Kawasaki
Ernest S
ES
NCI Advanced Technology Center, Bethesda, MD 20892, USA. kawasake@mail.nih.gov
D035061:Control Groups; D020869:Gene Expression Profiling / Q000592:standards*; D020411:Oligonucleotide Array Sequence Analysis / Q000592:standards*; D012313:RNA / Q000592:standards*; D015203:Reproducibility of Results
D012313:RNA